Login / Register The Most Trusted Name in Medical Education

Dermatology

Look no further for the gold standard in dermatology continuing medical education. Receive AMA PRA Category 1 Credit™ for taking any of our complimentary courses.

DERM 116x140

Perspectives from the American Academy of Dermatology 2017 Meeting: Clinical Strategies and Scientific Advances in Atopic Dermatitis

Format: Webcast

After many years of little movement in new therapies for patients with atopic dermatitis (AD), significant growth in researching the pathogenesis of AD has resulted in a better understanding of its causes, which has led to new protein targets for novel monoclonal antibodies (mABs). Often diagnosed in infancy, AD can persist into adulthood, affecting 3% to 5% of adults in the United States. Approximately 20% of children and adult patients have been diagnosed with moderate-to-severe AD. For this patient population, these latest advances continue to offer hope, as the current standard of care, which largely centers on symptom management, is suboptimal. This enduring video-based roundtable activity provides the latest updates on AD, including data on emerging and novel treatment options. Expert clinical faculty will also discuss the latest research in AD presented at the 41st Annual Hawaii Dermatology Seminar.  

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
2017 19 116x140

Perspectives from the American Academy of Dermatology 2017 Meeting: Clinical Strategies and Scientific Advances in Atopic Dermatitis

Format: Webcast

After many years of little movement in new therapies for patients with atopic dermatitis (AD), significant growth in researching the pathogenesis of AD has resulted in a better understanding of its causes, which has led to new protein targets for novel monoclonal antibodies (mABs). Often diagnosed in infancy, AD can persist into adulthood, affecting 3% to 5% of adults in the United States. Approximately 20% of children and adult patients have been diagnosed with moderate-to-severe AD. For this patient population, these latest advances continue to offer hope, as the current standard of care, which largely centers on symptom management, is suboptimal. This enduring video-based roundtable activity provides the latest updates on AD, including data on emerging and novel treatment options. Expert clinical faculty will also discuss the latest research on AD presented at the American Academy of Dermatology 2017 Annual Meeting.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™